- Home
- CCAP vs ORIC Comparison
CCAP vs ORIC Comparison
Compare CCAP & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCAP
- ORIC
- Stock Information
- Founded
- CCAP 2015
- ORIC 2014
- Country
- CCAP United States
- ORIC United States
- Employees
- CCAP N/A
- ORIC N/A
- Industry
- CCAP Finance: Consumer Services
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- CCAP Finance
- ORIC Health Care
- Exchange
- CCAP Nasdaq
- ORIC Nasdaq
- Market Cap
- CCAP 706.0M
- ORIC 735.3M
- IPO Year
- CCAP N/A
- ORIC 2020
- Fundamental
- Price
- CCAP $18.44
- ORIC $7.68
- Analyst Decision
- CCAP Buy
- ORIC Strong Buy
- Analyst Count
- CCAP 6
- ORIC 10
- Target Price
- CCAP $19.17
- ORIC $19.13
- AVG Volume (30 Days)
- CCAP 112.8K
- ORIC 1.6M
- Earning Date
- CCAP 02-19-2025
- ORIC 02-18-2025
- Dividend Yield
- CCAP 1.08%
- ORIC N/A
- EPS Growth
- CCAP N/A
- ORIC N/A
- EPS
- CCAP 1.99
- ORIC N/A
- Revenue
- CCAP $197,363,000.00
- ORIC N/A
- Revenue This Year
- CCAP $9.80
- ORIC N/A
- Revenue Next Year
- CCAP N/A
- ORIC N/A
- P/E Ratio
- CCAP $9.28
- ORIC N/A
- Revenue Growth
- CCAP 7.18
- ORIC N/A
- 52 Week Low
- CCAP $16.58
- ORIC $6.33
- 52 Week High
- CCAP $20.19
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- CCAP 29.87
- ORIC 36.65
- Support Level
- CCAP $19.46
- ORIC $7.34
- Resistance Level
- CCAP $20.19
- ORIC $14.67
- Average True Range (ATR)
- CCAP 0.34
- ORIC 1.56
- MACD
- CCAP -0.10
- ORIC -0.45
- Stochastic Oscillator
- CCAP 7.41
- ORIC 4.64
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.